Compare BridgeBio Pharma Inc (BBIO) vs Nerdwallet Inc (NRDS) Price & Performance

BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.

The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.

NerdWallet (NRDS) trades at $9.91, up 12.1% in the past 24 hours, with a bullish technical signal from moving averages. The company shows strong revenue growth from $539M in 2022 to $837M in 2025, with net income turning positive to $48.7M. Recent Q2 2026 earnings missed expectations at $0.07 per share versus $0.0934 expected, though Q1 and Q4 2025 beat estimates. Valuation metrics appear attractive with a P/E of 10.9 and P/S of 0.82.

The outlook remains positive with analyst consensus favoring Buy ratings (66.7%) and projected 27.9% upside potential. Key risks include execution challenges in shifting from SEO-dependent referrals and competitive pressure in financial guidance markets. Strong cash flow generation and improving profitability support the bullish case, though investors should monitor quarterly earnings consistency.